Med
Volume 1, Issue 1, 18 December 2020, Pages 105-113.e4
Clinical AdvancesEfficacy and Safety of Lopinavir/Ritonavir or Arbidol in Adult Patients with Mild/Moderate COVID-19: An Exploratory Randomized Controlled Trial
Under an Elsevier user license
open archive
Context and Significance
The coronavirus SARS-CoV-2 is causing the current COVID-19 pandemic, which has affected over 1 million people worldwide. As the scientific community researches new treatments against the disease, drugs that have already been approved for other viruses are also being tested. Here, clinicians from Guangzhou Medical University tested lopinavir/ritonavir and arbidol, which are currently used against HIV-1 and influenza, respectively, in patients with mild or moderate COVID-19. The authors show that neither drug improves the recovery compared to standard care, suggesting that treatment with either drug may not be beneficial against COVID-19 and other therapies may be a more effective choice.
Graphical Abstract
Keywords
COVID-19
SARS-CoV-2
lopinavir/ritonavir
arbidol
efficacy
Keywords
CAT Scale: Translation to patients
Cited by (0)
© 2020 Published by Elsevier Inc.